Hyperthermia for Treatment of Cancer | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for hyperthermia in cancer treatment, effective May 15, 2026. Here's what billing teams need to know before that date.

CMS hyperthermia cancer coverage policy has been a moving target for years. This modification signals a meaningful shift in how Medicare approaches heat-based cancer therapy — a modality that sits at the intersection of oncology, radiation therapy, and interventional treatment. The policy does not list specific CPT or HCPCS codes in the available data, so your first task is pulling the full policy text and matching it against your charge master before May 15, 2026.

Quick-Reference Table

CMS Hyperthermia Cancer Coverage Criteria and Medical Necessity Requirements 2026

Hyperthermia as a cancer treatment uses elevated tissue temperatures — typically between 40°C and 45°C — to damage or kill cancer cells, often in combination with radiation or chemotherapy. CMS has historically treated this modality with significant skepticism, covering it narrowly and only when specific clinical conditions are met.

The core question in any CMS hyperthermia coverage policy review is whether medical necessity can be established and documented at the claim level. CMS requires that hyperthermia be delivered as an adjunct to radiation therapy in most covered indications — standalone hyperthermia as a primary cancer treatment has not been a covered benefit under traditional Medicare coverage frameworks. Your documentation needs to reflect that distinction clearly.

Medical necessity under this policy hinges on the type of hyperthermia used, the cancer site, and the treatment context. CMS has historically differentiated between local hyperthermia (applied to a defined tumor region), regional hyperthermia (applied to a larger body area or organ), and whole-body hyperthermia — and coverage status differs across those categories. The modification effective May 15, 2026 may shift which of those modalities CMS considers medically necessary versus experimental.

Prior authorization is not universally required for hyperthermia under Medicare fee-for-service, but Medicare Advantage plans have their own prior auth rules. If your patients are Medicare Advantage enrollees, check each plan's coverage policy separately — do not assume the CMS national policy applies one-to-one to MA plan benefits.

Whether CMS hyperthermia reimbursement is covered under Medicare also depends on the setting. Hospital outpatient departments billing under the Outpatient Prospective Payment System (OPPS) and freestanding radiation therapy centers bill hyperthermia differently. Confirm your billing guidelines align with your site of service before May 15, 2026.

CMS Hyperthermia Cancer Exclusions and Non-Covered Indications

CMS has long held that several hyperthermia applications lack sufficient clinical evidence for routine coverage. Whole-body hyperthermia — where core body temperature is elevated systemically — has generally been classified as experimental or investigational under national coverage frameworks. That classification may be addressed in this modification, but until you review the full policy text, treat it as non-covered.

Regional hyperthermia applied outside of specific cancer types and clinical contexts has also faced non-coverage determinations. The real issue here is that CMS draws a hard line between hyperthermia as an evidence-supported adjunct to radiation in superficial tumors and hyperthermia as a broader therapeutic tool. If your providers are using deep regional hyperthermia for recurrent or refractory cancers, your claim denial risk is elevated without airtight documentation.

Hyperthermia delivered without concurrent or recent radiation therapy — meaning as a standalone intervention — falls outside covered indications in most Medicare coverage scenarios. Train your billing team to flag any hyperthermia claim that lacks an associated radiation therapy claim before submission.

Coverage Indications at a Glance

The specific policy document for this modification does not include available code-level data in the source provided. The table below reflects the historical CMS coverage framework for hyperthermia, which this modification builds on. Review the full policy at the effective date to confirm current status.

CMS Hyperthermia Cancer Billing Guidelines and Action Items 2026

This modification requires action before May 15, 2026 — not after your first denial.

CPT, HCPCS, and ICD-10 Codes for Hyperthermia Under CMS Cancer Treatment Policy

The available policy data for this modification does not include specific CPT, HCPCS, or ICD-10 codes. This is not unusual for CMS national policy modifications — the code-level detail is often embedded in the full policy document or in MAC-level LCDs rather than the summary record.

Do not rely on this blog post for code-level billing decisions on this policy. Pull the full policy from CMS directly. Your MAC may also publish a companion LCD with specific codes, covered diagnoses, and non-covered indications that carry equal weight for billing purposes.

What to Look For in the Full Policy

When you pull the full text, focus on three things. First, identify which CPT codes appear under covered indications — these will drive your charge capture setup. Second, note any CPT codes listed under non-covered or experimental designations — these need a flag in your billing workflow. Third, check whether specific ICD-10-CM diagnosis codes are required to establish medical necessity, because hyperthermia coverage is often limited to particular cancer types or tumor sites.

If you need help matching hyperthermia CPT codes to the updated coverage criteria, your billing consultant or MAC provider outreach representative can walk you through it. This is the right time to use those resources — before the effective date, not after a string of denials.